Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Photopheresis in Early-stage Mycosis Fungoides

NCT: NCT05680558 · RECRUITING

NCT IDNCT05680558
StatusRECRUITING
Start Date2021-05-08
Completion2028-07

Brief Summary

The purpose of this study is to determine whether photopheresis therapy can be used to improve the clinical course of early stage cutaneous T-cell lymphoma (CTCL). Currently, photopheresis is performed as a palliative treatment for late stage CTCL. However, recent studies have demonstrated that patients with early stage CTCL may have markers in their blood which were previously observed primarily in late stage disease, such as clonal T cell populations. Considering these findings, the study aims to investigate whether photopheresis therapy may be used earlier in the disease course to produce a clinical response.

Frequently Asked Questions

What is Photopheresis in Early-stage Mycosis Fungoides?

Photopheresis in Early-stage Mycosis Fungoides is a clinical trial registered under NCT05680558. Current status: RECRUITING.

What is the status of NCT05680558?

The current status of NCT05680558 (Photopheresis in Early-stage Mycosis Fungoides) is: RECRUITING.

When did Photopheresis in Early-stage Mycosis Fungoides start?

Photopheresis in Early-stage Mycosis Fungoides started on 2021-05-08.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.